MERGER WITH CSL III (Tables)

3 Months Ended

Mar. 31, 2026

Business Combination, Asset Acquisition, Transaction between Entities under Common Control, and Joint Venture Formation [Abstract]

Schedule of Asset Acquisition

The following table summarizes the allocation of the purchase price to the assets acquired and liabilities assumed as a result of the CSL III Merger:


Common stock issued by the Company(1)	$	315,838
Cash paid in lieu of fractional shares	4
Transaction costs	1,650
Total purchase price	$	317,492
Assets acquired:
Investments, at fair value	$	483,736
Cash and cash equivalents(2)	37,751
Interest receivable	7,909
Other assets	9,907
Total assets acquired	$	539,303
Liabilities assumed:
Debt	$	206,000
Derivative liabilities, at fair value	812
Other liabilities(3)	16,918
Total liabilities assumed	$	223,730
Net assets acquired	$	315,573
Total purchase premium	$	1,919

(1)Based on a market price at closing of $16.68 per share and 18,935,108 shares of common stock issued by the Company in conjunction with the CSL III Merger to former CSL III shareholders.

(2)Includes all unrestricted and restricted cash and cash equivalents acquired at closing.

(3)Includes accrued expenses, incentive fees, and other liabilities assumed as part of the merger.

Schedule of Outstanding Forward Currency Contracts

Below is a summary of the outstanding forward currency contracts assumed as of March 27, 2025. All the forward currency contracts assumed from the CSL III Merger were closed on March 31, 2025.


Counterparty	Notional Amount to be Purchased		Notional Amount to be Sold		Unrealized Appreciation (Depreciation)
Macquarie Bank Limited	$	3,081	€	2,827	$	(14)
Macquarie Bank Limited	$	3,678	C$	4,967	90

Barclays Bank PLC	$	21,877	€	20,525	(601)
Barclays Bank PLC	$	6,781	£	5,485	(288)
Barclays Bank PLC	€	18	$	19	1
					$	(812)